Holen Sie sich die Stockscreener-App
1.385
2.59%
0.035
Handel nachbörslich:
1.28
-0.105
-7.58%
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
Calidi Biotherapeutics Inc. (NYSE: CLDI) Share Price, CLDI Stock News, CLDI Share Price & Updates - Kalkine
CLDI Q4 2025 Earnings: Loss Narrows Sharply, Beating Estimates by 73.59%; Shares Rise 3.41%Dividend Earnings Report - vinanet.vn
ARMISTICE CAPITAL, LLC Slashes Calidi Biotherapeutics (CLDI) Sta - GuruFocus
Calidi Biotherapeutics (CLDI) grants director 5,000 options - Stock Titan
Calidi director granted 4,000 options at $1.36 | CLDI Insider Trading - Stock Titan
Calidi Biotherapeutics (CLDI) gives CFO 14,000 options with 10-year term - Stock Titan
Calidi Biotherapeutics (CLDI) awards director 4,000 options vesting in 1 year - Stock Titan
Calidi Biotherapeutics (CLDI) CEO awarded 32K options vesting over 4 years - Stock Titan
Calidi (CLDI) Report Card: The EPS Result Is Above Expectation in the Current Update; Reaction Snapshot: Shares Close 6.62% Lower in the Latest SessionTrough Earnings Signal - vinanet.vn
Calidi (CLDI) Closing Snapshot: Retreats 5.59% to $1.28 in the Current Update; Technical Position: the Near-Term Reference Band Stretches From $1.22 to $1.34 on the DayCalendar Spread Trade - vinanet.vn
Calidi Biotherapeutics Granted Patent for Cell-Based Oncolytic Virus Immunotherapy for Cancer Treatment - ACCESS Newswire
Armistice Capital reports 4.99% Calidi Biotherapeutics (CLDI) stake in Schedule 13G/A - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 8K Calidi Biotherapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Calidi Biotherapeutics Reports Quarterly Results and Pipeline Progress - TipRanks
Calidi Biotherapeutics Q2 net loss narrows to $4.2M; G&A cuts 48% - scanx.trade
Calidi Biotherapeutics 2Q 2026: Net loss $4.16M, EPS $(2.94) — 10-Q Summary - TradingView
Calidi Biotherapeutics Reports Positive FDA Pre-IND Feedback for CLD-401, Showcases RedTail Platform Data and Cuts G&A Expenses - Quiver Quantitative
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Price to book forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Price to sales forward of Calidi Biotherapeutics Inc. – OTC:CLDWW - TradingView
Calidi Biotherapeutics Inc (CLDI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Calidi Biotherapeutics (CLDI) Holds Steady at $1.63 as Stock Sits Between Support and ResistanceEntry Point Alerts - dars.gov.et
CLDI Q4 2025 Earnings: Narrower Loss of -$0.43 Per Share Beats Estimates, Stock Falls 9.5%High Estimate Range - vinanet.vn
Calidi Biotherapeutics (CLDI) Insider Trading Activity 2026 $CLDI - MarketBeat
Calidi Biotherapeutics (CLDI) Falls 6.88% to $1.76, Pressing Key Support at $1.67MACD Signal Stocks - dars.gov.et
Calidi Biotherapeutics (CLDI) Jumps 12.5% to $1.89 as Bullish Momentum Builds Toward $1.98 ResistanceSector Neutral Pair - vinanet.vn
Price to sales forward of Calidi Biotherapeutics, Inc. – BOATS:CLDI - TradingView
Calidi Biotherapeutics (CLDI) Surges 9.86% to $1.64 as Buying Pressure BuildsGolden Cross - vinanet.vn
Calidi Biotherapeutics Announces Reverse Stock Split to Maintain NYSE American Listing – July 2026 8-K Filing - Minichart
Calidi Biotherapeutics Implements Reverse Stock Split on NYSE - TipRanks
Price to book forward of Calidi Biotherapeutics, Inc. – AMEX:CLDI - tradingview.com
Calidi Biotherapeutics Inc (CLDI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CLDI|Calidi Biotherapeutics Inc|Price:0.109|Chg%:+0.009 - TradingKey
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference - GlobeNewswire
Calidi Biotherapeutics Inc (CLDI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Calidi highlights new EpCam-targeting T-cell engager data - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Calidi Biotherapeutics Inc (CLDI) Cash Flow - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
TradingKey - TradingKey
CLDI Q4 2025 Earnings: Smaller-Than-Expected Loss Fails to Lift SharesGrowth Acceleration Report - vinanet.vn
Calidi Biotherapeutics Inc (CLDI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Calidi Biotherapeutics (CLDI) Holds at $0.1 Support After Minor DeclinePut Support - vinanet.vn
Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK
Calidi Biotherapeutics To Carry Out 1-for-16 Reverse Stock Split On July 31st, 2026 - Moomoo
Calidi Gains on Company Update - Baystreet.ca
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - The Manila Times
Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split - marketscreener.com
Calidi Announces Reverse Stk Split, Expected to Begin Trading on a 1-For-16 Split Adjusted Basis on July 31 - Moomoo
Calidi shareholders will get one share for every 16 held - Stock Titan
CLDI Q4 2025 Earnings: EPS Beats Estimates by 73.6% as Company Advances Clinical PipelineOperating Income Trends - vinanet.vn
Calidi Biotherapeutics Plans Relocation Through New Lease Agreements - TipRanks
Calidi Biotherapeutics Signs 44-Month Lease at 5580 Morehouse Drive, San Diego for New Corporate Headquarters - Minichart
New lease could save Calidi Biotherapeutics (NYSE American: CLDI) $1.1M yearly - Stock Titan
CLDI Q4 2025 Earnings: EPS Beat by 73.59% Despite No RevenueEarnings Season Outlook - vinanet.vn
Calidi Biotherapeutics (CLDI) Slides Over 8% as Stock Nears Critical Support Level at $0.11Breakout Trade - vinanet.vn
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi lures new finance chief with 100,000 stock options - Stock Titan
Calidi Biotherapeutics grants inducement options to new VP Finance - scanx.trade
0.86%
0.31%
Kapitalisierung:
|
Volumen (24h):